

Phathom[®]

PHARMACEUTICALS

Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 7, 2024

February 29, 2024

- *Management to host conference call on Thursday, March 7, 2024, at 8:30 a.m. ET*

FLORHAM PARK, N.J., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it will host a live webcast at 8:30 am ET on Thursday, March 7, 2024, to report its fourth quarter and full year 2023 financial results and provide recent business progress.

A live webcast and additional information about the presentation can be accessed on News & Events section of the Phathom website at <https://investors.phathompharma.com/news-events/events-and-presentations>. Participants can register for the call [here](#). Recordings will be available for 90 days following the conclusion of the meeting.

About Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) which it currently markets in the United States as VOQUEZNA[®] (vonoprazan) tablets for the treatment of Erosive GERD and relief of heartburn associated with Erosive GERD in adults, in addition to VOQUEZNA[®] TRIPLE PAK[®] (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) and VOQUEZNA[®] DUAL PAK[®] (vonoprazan tablets, amoxicillin capsules) for the treatment of *H. pylori* infection in adults. For more information about Phathom, visit the Company's website at www.phathompharma.com and follow the Company on [LinkedIn](#) and [X](#).

MEDIA CONTACT

Nick Benedetto
1-877-742-8466
media@phathompharma.com

INVESTOR CONTACT

Eric Sciorilli
1-877-742-8466
ir@phathompharma.com

© 2024 Phathom Pharmaceuticals. All rights reserved.